as on October 29, 2025 at 1:29 am IST
Day's Low
Day's High
2.07%
Downside
2.10%
Upside
52 Week's Low
52 Week's High
89.34%
Downside
8.19%
Upside
Check Nektar Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.2B
EPS (TTM)
-10.3548
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-1.32
Industry PE ratio
-2.817555555555556
PEG Ratio
3.22
EBITDA
-137.2M
Revenue (TTM)
74.9M
Profit Margin
-163.17%
Return On Equity TTM
-440.80%
Track how Nektar Therapeutics P/E has moved over time to understand its valuation trends.
Nektar Therapeutics in the last 5 years
Lowest (-130.77x)
March 31, 2021
Industry (-2.82x)
October 29, 2025
Today (-1.32x)
October 29, 2025
Highest (-3.35x)
June 30, 2025
Today’s Price to Earnings Ratio: -1.32x
Compare market cap, revenue, PE, and other key metrics of Nektar Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| HOLD | $1.2B | -74.95% | -1.32 | -163.17% | |
| BUY | $62.7B | 285.91% | -505.15 | -12.96% | |
| NA | $36.5B | NA | NA | -3.89% | |
| BUY | $108.0B | 104.04% | 29.95 | 31.86% | |
| BUY | $62.0B | 17.76% | 14.75 | 31.37% |
The Nektar Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Nektar Therapeutics investment value today
Current value as on today
₹3,24,274
Returns
₹2,24,274
(+224.27%)
Returns from Nektar Therapeutics Stock
₹2,19,213 (+219.21%)
Dollar Returns*
₹5,061 (+5.06%)
Based on 9 analysts
0.00%
Buy
55.56%
Hold
44.44%
Sell
Based on 9 analysts, 55.56% of analysts recommend a 'HOLD' rating for Nektar Therapeutics. Average target price of $93.86
Get share price movements and forecasts by analysts on Nektar Therapeutics.
What analysts predicted
35.21%UPSIDE
Target Price
$93.86
Current Price
$60.81
Analyzed by
9 Analysts
Target
$93.86
Nektar Therapeutics target price $93.86, a slight upside of 35.21% compared to current price of $60.81. According to 9 analysts rating.
Search interest for Nektar Therapeutics Stock has decreased by -69% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 1 Year
![]()
In the last 1 year, NKTR has outperformed top 5 stocks with highest market-cap in its industry
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 10.46M → 11.17M (in $), with an average increase of 6.4% per quarter
Price Rise
![]()
In the last 3 months, NKTR stock has moved up by 165.9%
Profit Spike
![]()
Netprofit is up for the last 2 quarters, -50.88M → -41.59M (in $), with an average increase of 22.3% per quarter
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 132.7% return, outperforming this stock by 124.7%
| Organisation | Nektar Therapeutics |
| Headquarters | 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 |
| Industry | Health Technology |
| CEO | Mr. Howard W. Robin |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
Ms. Charleen Jue | Senior Vice President of Clinical Development Operations |
Mr. Howard W. Robin | CEO, President & Director |
Mr. Mark A. Wilson J.D. | Senior VP, Chief Legal Officer & Secretary |
Dr. Jonathan Zalevsky Ph.D. | Senior VP and Chief Research & Development Officer |
Mr. Jason Barnard | Chief Accounting Officer |
Mr. Robert Bacci | Chief People Officer and Head of Quality & Facilities |
Ms. Jennifer Ruddock | Chief Business Officer |
Ms. Sandra A. Gardiner | CFO and Principal Financial & Accounting Officer |
Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development & Manufacturing |
Nektar Therapeutics share price today is $60.81 as on at the close of the market. Nektar Therapeutics share today touched a day high of $62.09 and a low of $59.55.
Nektar Therapeutics share touched a 52 week high of $65.79 on and a 52 week low of $6.48 on . Nektar Therapeutics stock price today i.e. is closed at $60.81,which is 7.57% down from its 52 week high and 838.43% up from its 52 week low.
Nektar Therapeutics market capitalisation is $0.00T as on .
Indian investors can start investing in Nektar Therapeutics (NKTR) shares with as little as ₹88.178 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.78 in Nektar Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Nektar Therapeutics share’s latest price of $60.81 as on October 29, 2025 at 1:29 am IST, you will get 0.1644 shares of Nektar Therapeutics. Learn more about
fractional shares .
Nektar Therapeutics stock has given -74.95% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?